Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?
Tedeschi A, Frustaci AM, Mauro FR, Chiarenza A, Coscia M, Ciolli S, Reda G, Laurenti L, Varettoni M, Murru R, Baratè C, Sportoletti P, Greco A, Borella C, Rossi V, Deodato M, Biagi A, Zamprogna G, Pelle AC, Lapietra G, Vitale C, Morelli F, Cassin R, Fresa A, Cavalloni C, Postorino M, Ielo C, Cairoli R, Di Raimondo F, Montillo M, Del Poeta G. Tedeschi A, et al. Among authors: fresa a. Blood Adv. 2021 Dec 28;5(24):5490-5500. doi: 10.1182/bloodadvances.2021004824. Blood Adv. 2021. PMID: 34525181 Free PMC article.
Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region.
Autore F, Innocenti I, Corrente F, Del Principe MI, Rosati S, Falcucci P, Fresa A, Conte E, Limongiello MA, Renzi D, De Padua L, Andriani A, Pisani F, Cimino G, Tafuri A, Montanaro M, Mauro FR, Del Poeta G, Laurenti L. Autore F, et al. Among authors: fresa a. Front Oncol. 2020 Jun 10;10:848. doi: 10.3389/fonc.2020.00848. eCollection 2020. Front Oncol. 2020. PMID: 32587827 Free PMC article.
Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study.
Visentin A, Mauro FR, Cibien F, Vitale C, Reda G, Fresa A, Ciolli S, Pietrasanta D, Marchetti M, Murru R, Gentile M, Rigolin GM, Quaglia FM, Scarfò L, Sportoletti P, Pravato S, Piazza F, Coscia M, Laurenti L, Molica S, Foà R, Cuneo A, Trentin L. Visentin A, et al. Among authors: fresa a. Am J Hematol. 2022 Mar 1;97(3):E95-E99. doi: 10.1002/ajh.26437. Epub 2021 Dec 21. Am J Hematol. 2022. PMID: 34904743 Free article. Clinical Trial. No abstract available.
Correspondence in reference to the previously published manuscript: Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B-cell lymphomas.
Autore F, Fresa A, Innocenti I, Principe MID, Maglione R, Stefanizzi C, Pelliccia S, Romeo A, Cimino G, Papa E, Padua L, Andriani A, Mengarelli A, Tafuri A, Ditto C, Mauro FR, Del Poeta G, Laurenti L. Autore F, et al. Among authors: fresa a. Hematol Oncol. 2023 Aug;41(3):571-573. doi: 10.1002/hon.2989. Epub 2022 Mar 31. Hematol Oncol. 2023. PMID: 35319789
Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study.
Fresa A, Autore F, Piciocchi A, Catania G, Visentin A, Tomasso A, Moretti M, Vitale C, Chiarenza A, Morelli F, Sportoletti P, Marasca R, Sapienza G, Cuccaro A, Murru R, Sanna A, Patti C, Angeletti I, Coscia M, Trentin L, Pietrasanta D, Innocenti I, Laurenti L. Fresa A, et al. Blood Adv. 2022 Jul 12;6(13):3875-3878. doi: 10.1182/bloodadvances.2022006964. Blood Adv. 2022. PMID: 35789375 Free PMC article. No abstract available.
33 results